Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NH102 multiple ascending dose in healthy subjects
NCT07324408Phase 1Completed
- Sponsor
- Jiangsu Nhwa Pharmaceutical
- Start
- Mar 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NH-102 in major depressive disorder (MDD) (4 arms), sponsored by Jiangsu Nhwa Pharmaceutical. Primary endpoints: Adverse Events, Laboratory Parameters and 4 more. Started Mar 2022; status: completed.
02
Drugs
NH-102
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07324408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07324408.